NIMGenetics

Madrid, Spain Founded: 2007 • Age: 19 yrs Acquired By Veritas Genetics
Diagnostic solutions are developed using microarray and next-generation sequencing technologies.
Request Access

About NIMGenetics

NIMGenetics is a company based in Madrid (Spain) founded in 2007 was acquired by Veritas Genetics in January 2025.. NIMGenetics has raised $7.63 million across 2 funding rounds from investors including Veritas Genetics, European Union and Apposite Capital. NIMGenetics has completed 1 acquisition, including Gene Predictis. NIMGenetics offers products and services including TrisoNIM, GenoNIM, ExoNIM, and NIMSeq. NIMGenetics operates in a competitive market with competitors including MedGenome, Foundation Medicine, Personalis, Veritas Genetics and Burning Rock, among others.

  • Headquarter Madrid, Spain
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Medical Devices & Diagnostics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $7.63 M (USD)

    in 2 rounds

  • Latest Funding Round
    $7.63 M (USD), Series A

    May 10, 2017

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
  • Acquired by
    Veritas Genetics

    (Jan 20, 2025)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of NIMGenetics

NIMGenetics offers a comprehensive portfolio of products and services, including TrisoNIM, GenoNIM, ExoNIM, and NIMSeq. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Detects aneuploidies and deletions for prenatal diagnostics.

Enables genomic analysis for various medical applications.

Provides complete exome analysis for genetic disorders.

Offers sequencing services for prenatal and postnatal testing.

People of NIMGenetics
Headcount 50-200
Employee Profiles 8
Employee Profiles
People
Salomé Jackson
Marketing Research
People
Esther Martin Palomino
Talent Manager
People
Miguel Del Cerro
Director de Recursos Humanos y Comunicación Corporativa
People
Sandra Paredes Hernández
Marketing Assistant

Unlock access to complete

Funding Insights of NIMGenetics

NIMGenetics has successfully raised a total of $7.63M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $7.63 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $7.6M
  • First Round

    (01 Jan 2017)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2017 Amount Series A - NIMGenetics Valuation Apposite Capital
Jan, 2017 Amount Grant - NIMGenetics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in NIMGenetics

NIMGenetics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Veritas Genetics, European Union and Apposite Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Healthcare impact investments are managed by Apposite Capital.
Founded Year Domain Location
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
Founded Year Domain Location
Genetic testing products for health risks and traits are offered.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by NIMGenetics

NIMGenetics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Gene Predictis. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Genomic tests are developed for personalized medicine risks.
0
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - NIMGenetics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Nimgenetics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of NIMGenetics

NIMGenetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MedGenome, Foundation Medicine, Personalis, Veritas Genetics and Burning Rock, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
DNA sequencing, bioinformatics, and multiomics services are provided.
domain founded_year HQ Location
Genomics-based diagnostic tests for cancer are provided.
domain founded_year HQ Location
Genomic sequencing and diagnosis software is provided for healthcare.
domain founded_year HQ Location
Genetic testing products for health risks and traits are offered.
domain founded_year HQ Location
Personalized cancer diagnostics are developed using genomic big data analysis.
domain founded_year HQ Location
Drug and companion diagnostics for multi-drug resistant cancers are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Nimgenetics

Frequently Asked Questions about NIMGenetics

When was NIMGenetics founded?

NIMGenetics was founded in 2007 and raised its 1st funding round 10 years after it was founded.

Where is NIMGenetics located?

NIMGenetics is headquartered in Madrid, Spain. It is registered at Madrid, Madrid, Spain.

Is NIMGenetics a funded company?

NIMGenetics is a funded company, having raised a total of $7.63M across 2 funding rounds to date. The company's 1st funding round was a Grant of $260.91K, raised on Jan 01, 2017.

What does NIMGenetics do?

Diagnostic solutions based on microarray and next-generation sequencing technologies. The company develops products for both the clinical and research markets. It has three product families for clinical diagnostics TRISONIM, a non-invasive prenatal test for the most commonly diagnosed fetal abnormalities KARYONIM, a range of products for invasive fetal and neonatal testing for chromosomal abnormalities and ONCONIM, which contains one test for BRCA testing, and two gene panels for enabling precision medicine in cancer patients. In addition, NIMGenetics has NIMFISH which is a range of customized FISH probes and EXONIM for whole exome sequencing. NIMGenetics is certified by Life Technologies (now ThermoFisher) for exome sequencing.

Who are the top competitors of NIMGenetics?

NIMGenetics's top competitors include Foundation Medicine, MedGenome and Personalis.

What products or services does NIMGenetics offer?

NIMGenetics offers TrisoNIM, GenoNIM, ExoNIM, and NIMSeq.

How many acquisitions has NIMGenetics made?

NIMGenetics has made 1 acquisition, including Gene Predictis.

Who are NIMGenetics's investors?

NIMGenetics has 3 investors. Key investors include Veritas Genetics, European Union, and Apposite Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available